Nuvalent (NUVL) EBITDA (2020 - 2026)
Nuvalent's (NUVL) quarterly EBITDA came in at -$119.4 million in Q1 2026, down 25.94% YoY from -$161.2 million in Q1 2025, and down 16.8% on a QoQ basis from -$102.2 million in Q4 2025.
Nuvalent (NUVL) EBITDA (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of EBITDA data on file, last reported at -$119.4 million in Q1 2026.
- Quarterly EBITDA fell 25.94% year-over-year to -$119.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$438.9 million (down 36.05% YoY) and the FY2025 annual result came in at -$414.3 million, down 47.77% from the prior year.
- EBITDA slipped to -$119.4 million in Q1 2026, from -$102.2 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$17.7 million in Q1 2022 to a low of -$119.4 million in Q1 2026.
- A 5-year average of -$61.7 million and a median of -$52.6 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA sank 187.05% — and 2025, when it fell 18.46%.
- Tracing NUVL's EBITDA over 5 years: stood at -$29.3 million in 2022, then plunged by 58.49% to -$46.4 million in 2023, then plunged by 85.84% to -$86.3 million in 2024, then fell by 18.46% to -$102.2 million in 2025, then decreased by 16.8% to -$119.4 million in 2026.
- The last three EBITDA figures came in at -$119.4 million (Q1 2026), -$102.2 million (Q4 2025), and -$112.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -119.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.41 Mn |
| Dec 31, 2025 | -102.23 Mn |
| Sep 30, 2025 | -112.70 Mn |
| Jun 30, 2025 | -104.57 Mn |
| Mar 31, 2025 | -94.81 Mn |
| Dec 31, 2024 | -86.30 Mn |
| Sep 30, 2024 | -76.33 Mn |
| Jun 30, 2024 | -65.15 Mn |
| Mar 31, 2024 | -52.59 Mn |
| Dec 31, 2023 | -46.44 Mn |
| Sep 30, 2023 | -38.78 Mn |
| Jun 30, 2023 | -34.06 Mn |
| Mar 31, 2023 | -30.21 Mn |
| Dec 31, 2022 | -29.30 Mn |
| Sep 30, 2022 | -20.39 Mn |
| Jun 30, 2022 | -18.73 Mn |
| Mar 31, 2022 | -17.69 Mn |
| Dec 31, 2021 | -17.38 Mn |
| Sep 30, 2021 | -12.43 Mn |
| Jun 30, 2021 | -9.85 Mn |